Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
| Autor: | Anna Schildt, Jens Kurth, Bernd J. Krause, Sarah M. Schwarzenböck, Alexander Tonn, Martin Heuschkel, Oliver W. Hakenberg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
single time-point
Cancer Research Quantitative imaging Dose calculation 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine PSMA Image acquisition Medicine Dosimetry RC254-282 therapy Simplified methods Whole-Body Scintigraphy dosimetry business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease prostate cancer Oncology 030220 oncology & carcinogenesis Absorbed dose business Nuclear medicine |
| Zdroj: | Cancers Volume 13 Issue 15 Cancers, Vol 13, Iss 3884, p 3884 (2021) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13153884 |
| Popis: | (Background) Aim of this retrospective analysis was to investigate in mCRPC patients treated with [177Lu]Lu-PSMA-617 whether the absorbed dose (AD) in organs at risk (OAR, i.e., kidneys and parotid glands) can be calculated using simplified methodologies with sufficient accuracy. For this calculation, results and kinetics of the first therapy cycle were used. (Methods) 46 patients treated with 2 to 6 cycles of [177Lu]Lu-PSMA-617 were included. As reference (current clinical standard) full dosimetry of the OAR based on quantitative imaging (whole body scintigraphy and quantitative SPECT/CT at 2, 24, 48 and 72 h p.i.) for every cycle was used. Alternatively, two dosimetry schemes, simplified in terms of image acquisition and dose calculation, were established, both assuming nearly unchanged kinetics of the radiopharmaceutical for subsequent cycles. (Results) In general, for both OAR the simplified methods provided results that were consistent with the dosimetric reference method, both per cycle and in terms of cumulative AD. Best results were obtained when imaging was performed at 48 h p.i. in each of the subsequent cycles. However, both simplified methods tended to underestimate the cumulative AD. (Conclusion) Simplified dosimetry schemes are feasible to tailor multi-cycle [177Lu]Lu-PSMA-targeted therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|